WUGEN Inc.

Clinical Update: News on Two Cancer Gene Editing...
Mar. 24, 2022

This week's update features Iovance Biotherapeutics' new cancer immunotherapy candidate IOV-4001 that was recently cleared for clinical trial...

News: CMN Weekly (17 December 2021) - Your Weekly...
Dec. 17, 2021

Some of the best links we picked up around the internet

WUGEN Inc.

T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma, (NCT06514794)
Sponsors:
Wugen, Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory T-cell Acute Lymphoblastic Leukaemia, T-ALL, (NCT05509855)
Sponsors:
Wugen, Inc.
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory T-cell Acute Lymphoblastic Leukaemia, T-ALL (NCT04984356)
Sponsors:
Wugen inc. 
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
close
Search CRISPR Medicine